Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 472

1.

Cost-effectiveness and budget effect of pre-exposure prophylaxis for HIV-1 prevention in Germany from 2018 to 2058.

van de Vijver DAMC, Richter AK, Boucher CAB, Gunsenheimer-Bartmeyer B, Kollan C, Nichols BE, Spinner CD, Wasem J, Schewe K, Neumann A.

Euro Surveill. 2019 Feb;24(7). doi: 10.2807/1560-7917.ES.2019.24.7.1800398.

2.

Early treatment of acute hepatitis C infection is cost-effective in HIV-infected men-who-have-sex-with-men.

Popping S, Hullegie SJ, Boerekamps A, Rijnders BJA, de Knegt RJ, Rockstroh JK, Verbon A, Boucher CAB, Nichols BE, van de Vijver DAMC.

PLoS One. 2019 Jan 10;14(1):e0210179. doi: 10.1371/journal.pone.0210179. eCollection 2019.

3.

Reply to Darcis and Berkhout.

Wijting IEA, Lungu C, Rijnders BJA, van der Ende ME, Pham HT, Mesplede T, Pas SD, Voermans JJC, Schuurman R, van de Vijver DAMC, Boers PHM, Gruters RA, Boucher CAB, van Kampen JJA.

J Infect Dis. 2018 Nov 5;218(12):2020-2021. doi: 10.1093/infdis/jiy475. No abstract available.

PMID:
30085047
4.

The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis C.

Popping S, Cento V, García F, Ceccherini-Silberstein F, Seguin-Devaux C, Vijver DA, Boucher CA.

J Virus Erad. 2018 Jul 1;4(3):179-181.

5.

Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe.

Colagrossi L, Hermans LE, Salpini R, Di Carlo D, Pas SD, Alvarez M, Ben-Ari Z, Boland G, Bruzzone B, Coppola N, Seguin-Devaux C, Dyda T, Garcia F, Kaiser R, Köse S, Krarup H, Lazarevic I, Lunar MM, Maylin S, Micheli V, Mor O, Paraschiv S, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Simon F, Stanojevic M, Stene-Johansen K, Tihic N, Trimoulet P, Verheyen J, Vince A, Lepej SZ, Weis N, Yalcinkaya T, Boucher CAB, Wensing AMJ, Perno CF, Svicher V; HEPVIR working group of the European Society for translational antiviral research (ESAR).

BMC Infect Dis. 2018 Jun 1;18(1):251. doi: 10.1186/s12879-018-3161-2.

6.

State of the Art in HIV Drug Resistance: Science and Technology Knowledge Gap.

Boucher CA, Bobkova MR, Geretti AM, Hung CC, Kaiser R, Marcelin AG, Streinu-Cercel A, van Wyk J, Dorr P, Vandamme AM.

AIDS Rev. 2018 Jan-Mar;20(1):27-42. Review.

PMID:
29628515
7.

State of the Art in HIV Drug Resistance: Surveillance and Regional Gaps.

Boucher CA, Bobkova MR, Hung CC, Kaiser R, Marcelin AG, Streinu-Cercel A, van Wyk J, Dorr P, Vandamme AM.

AIDS Rev. 2018 Jan-Mar;20(1):43-57. Review.

PMID:
29628514
8.

The S230R Integrase Substitution Associated With Virus Load Rebound During Dolutegravir Monotherapy Confers Low-Level Resistance to Integrase Strand-Transfer Inhibitors.

Pham HT, Labrie L, Wijting IEA, Hassounah S, Lok KY, Portna I, Goring ME, Han Y, Lungu C, van der Ende ME, Brenner BG, Boucher CA, Rijnders BJA, van Kampen JJA, Mesplède T, Wainberg MA.

J Infect Dis. 2018 Jul 24;218(5):698-706. doi: 10.1093/infdis/jiy175.

9.

HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy.

Wijting IEA, Lungu C, Rijnders BJA, van der Ende ME, Pham HT, Mesplede T, Pas SD, Voermans JJC, Schuurman R, van de Vijver DAMC, Boers PHM, Gruters RA, Boucher CAB, van Kampen JJA.

J Infect Dis. 2018 Jul 24;218(5):688-697. doi: 10.1093/infdis/jiy176.

PMID:
29617822
10.

Insights on transmission of HIV from phylogenetic analysis to locally optimize HIV prevention strategies.

van de Vijver DAMC, Boucher CAB.

Curr Opin HIV AIDS. 2018 Mar;13(2):95-101. doi: 10.1097/COH.0000000000000443. Review.

PMID:
29266012
11.

Ending the epidemic: Critical role of primary HIV infection.

Prins HAB, Verbon A, Boucher CAB, Rokx C.

Neth J Med. 2017 Oct;75(8):321-327. Review.

12.

Declining Hepatitis C Virus (HCV) Incidence in Dutch Human Immunodeficiency Virus-Positive Men Who Have Sex With Men After Unrestricted Access to HCV Therapy.

Boerekamps A, van den Berk GE, Lauw FN, Leyten EM, van Kasteren ME, van Eeden A, Posthouwer D, Claassen MA, Dofferhoff AS, Verhagen DWM, Bierman WF, Lettinga KD, Kroon FP, Delsing CE, Groeneveld PH, Soetekouw R, Peters EJ, Hullegie SJ, Popping S, van de Vijver DAMC, Boucher CA, Arends JE, Rijnders BJ.

Clin Infect Dis. 2018 Apr 17;66(9):1360-1365. doi: 10.1093/cid/cix1007.

PMID:
29186320
13.

Enrichment allows identification of diverse, rare elements in metagenomic resistome-virulome sequencing.

Noyes NR, Weinroth ME, Parker JK, Dean CJ, Lakin SM, Raymond RA, Rovira P, Doster E, Abdo Z, Martin JN, Jones KL, Ruiz J, Boucher CA, Belk KE, Morley PS.

Microbiome. 2017 Oct 17;5(1):142. doi: 10.1186/s40168-017-0361-8.

14.

A Summary of the Second Annual HIV Microbiome Workshop.

Williams B, Ghosh M, Boucher CAB, Bushman F, Carrington-Lawrence S, Collman RG, Dandekar S, Dang Q, Malaspina A, Paredes R, Wilson CC, Nowak P, Klatt NR, Lagenaur L, Landay AL.

AIDS Res Hum Retroviruses. 2017 Dec;33(12):1258-1264. doi: 10.1089/aid.2017.0137. Epub 2017 Oct 26.

15.

Identification of HCV Resistant Variants against Direct Acting Antivirals in Plasma and Liver of Treatment Naïve Patients.

Raj VS, Hundie GB, Schürch AC, Smits SL, Pas SD, Le Pogam S, Janssen HLA, de Knegt RJ, Osterhaus ADME, Najera I, Boucher CA, Haagmans BL.

Sci Rep. 2017 Jul 5;7(1):4688. doi: 10.1038/s41598-017-04931-y.

16.

Methodological concerns regarding a PrEP model - Authors' reply.

Nichols BE, Boucher CAB, van de Vijver DAM.

Lancet Infect Dis. 2017 May;17(5):482-483. doi: 10.1016/S1473-3099(17)30205-0. No abstract available.

PMID:
28447955
17.

Ending AIDS as a public health threat by 2030: Scientific Developments from the 2016 INTEREST Conference in Yaoundé, Cameroon.

Hankins CA, Koulla-Shiro S, Kilmarx P, Ferrari G, Schechter M, Kane CT, Venter F, Boucher CA, Ross AL, Zewdie D, Eholié SP, Katabira E.

Antivir Ther. 2017;22(2):179-184. doi: 10.3851/IMP3165. Epub 2017 Apr 7.

18.

Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study.

Nichols BE, Boucher CAB, van der Valk M, Rijnders BJA, van de Vijver DAMC.

Lancet Infect Dis. 2016 Dec;16(12):1423-1429. doi: 10.1016/S1473-3099(16)30311-5. Epub 2016 Sep 22.

PMID:
27665989
19.

Zika Virus: Where Is the Treatment?

Mumtaz N, van Kampen JJ, Reusken CB, Boucher CA, Koopmans MP.

Curr Treat Options Infect Dis. 2016;8:208-211. Epub 2016 Jul 8. Review. No abstract available.

20.

Unite forces to validate biomarkers in the quest for lasting HIV remission.

Rokx C, Vella S, Pantaleo G, Lévy Y, Boucher CA.

AIDS. 2016 Jul 17;30(11):1859-60. doi: 10.1097/QAD.0000000000001118. No abstract available.

PMID:
27351931
21.

A Summary of the First HIV Microbiome Workshop 2015.

Williams B, Mirmonsef P, Boucher CA, Bushman F, Carrington-Lawrence S, Collman RG, Dandekar S, Dang Q, Malaspina A, Paredes R, Stone A, Landay A.

AIDS Res Hum Retroviruses. 2016 Oct/Nov;32(10-11):935-941. Epub 2016 Jul 14.

22.

The global spread of HIV-1 subtype B epidemic.

Magiorkinis G, Angelis K, Mamais I, Katzourakis A, Hatzakis A, Albert J, Lawyer G, Hamouda O, Struck D, Vercauteren J, Wensing A, Alexiev I, Åsjö B, Balotta C, Gomes P, Camacho RJ, Coughlan S, Griskevicius A, Grossman Z, Horban A, Kostrikis LG, Lepej SJ, Liitsola K, Linka M, Nielsen C, Otelea D, Paredes R, Poljak M, Puchhammer-Stöckl E, Schmit JC, Sönnerborg A, Staneková D, Stanojevic M, Stylianou DC, Boucher CAB; SPREAD program, Nikolopoulos G, Vasylyeva T, Friedman SR, van de Vijver D, Angarano G, Chaix ML, de Luca A, Korn K, Loveday C, Soriano V, Yerly S, Zazzi M, Vandamme AM, Paraskevis D.

Infect Genet Evol. 2016 Dec;46:169-179. doi: 10.1016/j.meegid.2016.05.041. Epub 2016 Jun 2.

23.

Characterization of the resistome in manure, soil and wastewater from dairy and beef production systems.

Noyes NR, Yang X, Linke LM, Magnuson RJ, Cook SR, Zaheer R, Yang H, Woerner DR, Geornaras I, McArt JA, Gow SP, Ruiz J, Jones KL, Boucher CA, McAllister TA, Belk KE, Morley PS.

Sci Rep. 2016 Apr 20;6:24645. doi: 10.1038/srep24645.

24.

Resistome diversity in cattle and the environment decreases during beef production.

Noyes NR, Yang X, Linke LM, Magnuson RJ, Dettenwanger A, Cook S, Geornaras I, Woerner DE, Gow SP, McAllister TA, Yang H, Ruiz J, Jones KL, Boucher CA, Morley PS, Belk KE.

Elife. 2016 Mar 8;5:e13195. doi: 10.7554/eLife.13195.

25.

Dolutegravir as maintenance monotherapy: first experiences in HIV-1 patients.

Rokx C, Schurink CA, Boucher CA, Rijnders BJ.

J Antimicrob Chemother. 2016 Jun;71(6):1632-6. doi: 10.1093/jac/dkw011. Epub 2016 Feb 16.

PMID:
26888910
26.

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.

Hofstra LM, Sauvageot N, Albert J, Alexiev I, Garcia F, Struck D, Van de Vijver DAMC, Åsjö B, Beshkov D, Coughlan S, Descamps D, Griskevicius A, Hamouda O, Horban A, Van Kasteren M, Kolupajeva T, Kostrikis LG, Liitsola K, Linka M, Mor O, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnerborg A, Staneková D, Stanojevic M, Van Laethem K, Zazzi M, Zidovec Lepej S, Boucher CAB, Schmit JC, Wensing AMJ; SPREAD Program, Puchhammer-Stockl E, Sarcletti M, Schmied B, Geit M, Balluch G, Vandamme AM, Vercauteren J, Derdelinckx I, Sasse A, Bogaert M, Ceunen H, De Roo A, De Wit S, Echahidi F, Fransen K, Goffard JC, Goubau P, Goudeseune E, Yombi JC, Lacor P, Liesnard C, Moutschen M, Pierard D, Rens R, Schrooten Y, Vaira D, Vandekerckhove LPR, Van den Heuvel A, Van Der Gucht B, Van Ranst M, Van Wijngaerden E, Vandercam B, Vekemans M, Verhofstede C, Clumeck N, Van Laethem K, Beshkov D, Alexiev I, Lepej SZ, Begovac J, Kostrikis L, Demetriades I, Kousiappa I, Demetriou V, Hezka J, Linka M, Maly M, Machala L, Nielsen C, Jørgensen LB, Gerstoft J, Mathiesen L, Pedersen C, Nielsen H, Laursen A, Kvinesdal B, Liitsola K, Ristola M, Suni J, Sutinen J, Descamps D, Assoumou L, Castor G, Grude M, Flandre P, Storto A, Hamouda O, Kücherer C, Berg T, Braun P, Poggensee G, Däumer M, Eberle J, Heiken H, Kaiser R, Knechten H, Korn K, Müller H, Neifer S, Schmidt B, Walter H, Gunsenheimer-Bartmeyer B, Harrer T, Paraskevis D, Hatzakis A, Zavitsanou A, Vassilakis A, Lazanas M, Chini M, Lioni A, Sakka V, Kourkounti S, Paparizos V, Antoniadou A, Papadopoulos A, Poulakou G, Katsarolis I, Protopapas K, Chryssos G, Drimis S, Gargalianos P, Xylomenos G, Lourida G, Psichogiou M, Daikos GL, Sipsas NV, Kontos A, Gamaletsou MN, Koratzanis G, Sambatakou H, Mariolis H, Skoutelis A, Papastamopoulos V, Georgiou O, Panagopoulos P, Maltezos E, Coughlan S, De Gascun C, Byrne C, Duffy M, Bergin C, Reidy D, Farrell G, Lambert J, O'Connor E, Rochford A, Low J, Coakely P, O'Dea S, Hall W, Mor O, Levi I, Chemtob D, Grossman Z, Zazzi M, de Luca A, Balotta C, Riva C, Mussini C, Caramma I, Capetti A, Colombo MC, Rossi C, Prati F, Tramuto F, Vitale F, Ciccozzi M, Angarano G, Rezza G, Kolupajeva T, Vasins O, Griskevicius A, Lipnickiene V, Schmit JC, Struck D, Sauvageot N, Hemmer R, Arendt V, Michaux C, Staub T, Sequin-Devaux C, Wensing AMJ, Boucher CAB, van de Vijver DAMC, van Kessel A, van Bentum PHM, Brinkman K, Connell BJ, van der Ende ME, Hoepelman IM, van Kasteren M, Kuipers M, Langebeek N, Richter C, Santegoets RMWJ, Schrijnders-Gudde L, Schuurman R, van de Ven BJM, Åsjö B, Kran AB, Ormaasen V, Aavitsland P, Horban A, Stanczak JJ, Stanczak GP, Firlag-Burkacka E, Wiercinska-Drapalo A, Jablonowska E, Maolepsza E, Leszczyszyn-Pynka M, Szata W, Camacho R, Palma C, Borges F, Paixão T, Duque V, Araújo F, Otelea D, Paraschiv S, Tudor AM, Cernat R, Chiriac C, Dumitrescu F, Prisecariu LJ, Stanojevic M, Jevtovic D, Salemovic D, Stanekova D, Habekova M, Chabadová Z, Drobkova T, Bukovinova P, Shunnar A, Truska P, Poljak M, Lunar M, Babic D, Tomazic J, Vidmar L, Vovko T, Karner P, Garcia F, Paredes R, Monge S, Moreno S, Del Amo J, Asensi V, Sirvent JL, de Mendoza C, Delgado R, Gutiérrez F, Berenguer J, Garcia-Bujalance S, Stella N, de Los Santos I, Blanco JR, Dalmau D, Rivero M, Segura F, Elías MJP, Alvarez M, Chueca N, Rodríguez-Martín C, Vidal C, Palomares JC, Viciana I, Viciana P, Cordoba J, Aguilera A, Domingo P, Galindo MJ, Miralles C, Del Pozo MA, Ribera E, Iribarren JA, Ruiz L, de la Torre J, Vidal F, Clotet B, Albert J, Heidarian A, Aperia-Peipke K, Axelsson M, Mild M, Karlsson A, Sönnerborg A, Thalme A, Navér L, Bratt G, Karlsson A, Blaxhult A, Gisslén M, Svennerholm B, Bergbrant I, Björkman P, Säll C, Mellgren Å, Lindholm A, Kuylenstierna N, Montelius R, Azimi F, Johansson B, Carlsson M, Johansson E, Ljungberg B, Ekvall H, Strand A, Mäkitalo S, Öberg S, Holmblad P, Höfer M, Holmberg H, Josefson P, Ryding U.

Clin Infect Dis. 2016 Mar 1;62(5):655-663. doi: 10.1093/cid/civ963. Epub 2015 Nov 29.

27.

Partner Notification for Reduction of HIV-1 Transmission and Related Costs among Men Who Have Sex with Men: A Mathematical Modeling Study.

Nichols BE, Götz HM, van Gorp EC, Verbon A, Rokx C, Boucher CA, van de Vijver DA.

PLoS One. 2015 Nov 10;10(11):e0142576. doi: 10.1371/journal.pone.0142576. eCollection 2015.

28.

Treatment of Immunocompromised, Critically Ill Patients with Influenza A H1N1 Infection with a Combination of Oseltamivir, Amantadine, and Zanamivir.

Meijer WJ, Kromdijk W, van den Broek MP, Haas PJ, Minnema MC, Boucher CA, de Lange DW, Wensing AM.

Case Rep Infect Dis. 2015;2015:504975. doi: 10.1155/2015/504975. Epub 2015 Aug 9.

29.

Primary resistance to integrase strand-transfer inhibitors in Europe.

Casadellà M, van Ham PM, Noguera-Julian M, van Kessel A, Pou C, Hofstra LM, Santos JR, Garcia F, Struck D, Alexiev I, Bakken Kran AM, Hoepelman AI, Kostrikis LG, Somogyi S, Liitsola K, Linka M, Nielsen C, Otelea D, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Staneková D, Stanojevic M, Van Laethem K, Zidovec Lepej S, Clotet B, Boucher CA, Paredes R, Wensing AM; SPREAD programme.

J Antimicrob Chemother. 2015 Oct;70(10):2885-8. doi: 10.1093/jac/dkv202. Epub 2015 Jul 17.

PMID:
26188038
30.

Outcomes and Susceptibility to Neuraminidase Inhibitors in Individuals Infected With Different Influenza B Lineages: The Influenza Resistance Information Study.

van der Vries E, Ip DK, Cowling BJ, Zhang JD, Tong X, Wojtowicz K, Schutten M, Boucher CA.

J Infect Dis. 2016 Jan 15;213(2):183-90. doi: 10.1093/infdis/jiv375. Epub 2015 Jul 9.

PMID:
26160744
31.

Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE).

Hermans LE, Svicher V, Pas SD, Salpini R, Alvarez M, Ben Ari Z, Boland G, Bruzzone B, Coppola N, Seguin-Devaux C, Dyda T, Garcia F, Kaiser R, Köse S, Krarup H, Lazarevic I, Lunar MM, Maylin S, Micheli V, Mor O, Paraschiv S, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Simon F, Stanojevic M, Stene-Johansen K, Tihic N, Trimoulet P, Verheyen J, Vince A, Weis N, Yalcinkaya T, Lepej SZ, Perno C, Boucher CA, Wensing AM; HEPVIR Working Group of the European Society for Translational Antiviral Research.

J Infect Dis. 2016 Jan 1;213(1):39-48. doi: 10.1093/infdis/jiv363. Epub 2015 Jul 1.

PMID:
26136470
32.

Correction: Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis.

Rhee SY, Blanco JL, Jordan MR, Taylor J, Lemey P, Varghese V, Hamers RL, Bertagnolio S, de Wit TF, Aghokeng AF, Albert J, Avi R, Avila-Rios S, Bessong PO, Brooks JI, Boucher CA, Brumme ZL, Busch MP, Bussmann H, Chaix ML, Chin BS, D'Aquin TT, De Gascun CF, Derache A, Descamps D, Deshpande AK, Djoko CF, Eshleman SH, Fleury H, Frange P, Fujisaki S, Harrigan PR, Hattori J, Holguin A, Hunt GM, Ichimura H, Kaleebu P, Katzenstein D, Kiertiburanakul S, Kim JH, Kim SS, Li Y, Lutsar I, Morris L, Ndembi N, Kee PN, Paranjape RS, Peeters M, Poljak M, Price MA, Ragonnet-Cronin ML, Reyes-Terán G, Rolland M, Sirivichayakul S, Smith DM, Soares MA, Soriano VV, Ssemwanga D, Stanojevic M, Stefani MA, Sugiura W, Sungkanuparph S, Tanuri A, Tee KK, Truong HM, van de Vijver DA, Vidal N, Yang C, Yang R, Yebra G, Ioannidis JP, Vandamme AM, Shafer RW.

PLoS Med. 2015 Jun 1;12(6):e1001845. doi: 10.1371/journal.pmed.1001845. eCollection 2015 Jun. No abstract available.

33.

Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis.

Rhee SY, Blanco JL, Jordan MR, Taylor J, Lemey P, Varghese V, Hamers RL, Bertagnolio S, Rinke de Wit TF, Aghokeng AF, Albert J, Avi R, Avila-Rios S, Bessong PO, Brooks JI, Boucher CA, Brumme ZL, Busch MP, Bussmann H, Chaix ML, Chin BS, D'Aquin TT, De Gascun CF, Derache A, Descamps D, Deshpande AK, Djoko CF, Eshleman SH, Fleury H, Frange P, Fujisaki S, Harrigan PR, Hattori J, Holguin A, Hunt GM, Ichimura H, Kaleebu P, Katzenstein D, Kiertiburanakul S, Kim JH, Kim SS, Li Y, Lutsar I, Morris L, Ndembi N, Ng KP, Paranjape RS, Peeters M, Poljak M, Price MA, Ragonnet-Cronin ML, Reyes-Terán G, Rolland M, Sirivichayakul S, Smith DM, Soares MA, Soriano VV, Ssemwanga D, Stanojevic M, Stefani MA, Sugiura W, Sungkanuparph S, Tanuri A, Tee KK, Truong HM, van de Vijver DA, Vidal N, Yang C, Yang R, Yebra G, Ioannidis JP, Vandamme AM, Shafer RW.

PLoS Med. 2015 Apr 7;12(4):e1001810. doi: 10.1371/journal.pmed.1001810. eCollection 2015 Apr. Erratum in: PLoS Med. 2015 Jun;12(6):e1001845.

34.

Viral shedding and susceptibility to oseltamivir in hospitalized immunocompromised patients with influenza in the Influenza Resistance Information Study (IRIS).

Fraaij PL, Schutten M, Javouhey E, Burleigh L, Outlaw R, Kumar D, Boucher CA.

Antivir Ther. 2015;20(6):633-42. doi: 10.3851/IMP2957. Epub 2015 Apr 7.

PMID:
25849228
35.

Efficacy of tenofovir and efavirenz in combination with lamivudine or emtricitabine in antiretroviral-naive patients in Europe.

Swartz JE, Vandekerckhove L, Ammerlaan H, de Vries AC, Begovac J, Bierman WF, Boucher CA, van der Ende ME, Grossman Z, Kaiser R, Levy I, Mudrikova T, Paredes R, Perez-Bercoff D, Pronk M, Richter C, Schmit JC, Vercauteren J, Zazzi M, Židovec Lepej S, De Luca A, Wensing AM; European Society for translational Antiviral Research (ESAR).

J Antimicrob Chemother. 2015;70(6):1850-7. doi: 10.1093/jac/dkv033. Epub 2015 Mar 3.

PMID:
25740950
36.

Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity.

Pingen M, Wensing AM, Fransen K, De Bel A, de Jong D, Hoepelman AI, Magiorkinis E, Paraskevis D, Lunar MM, Poljak M, Nijhuis M, Boucher CA; SPREAD programme.

Retrovirology. 2014 Nov 29;11:105. doi: 10.1186/s12977-014-0105-9.

37.

Second European Round Table on the Future Management of HIV: 10-11 October 2014, Barcelona, Spain.

Rokx C, Richman DD, Müller-Trutwin M, Silvestri G, Lunzen J, Khoo S, Lichterfeld M, Altfeld M, Perno CF, Hunt PW, Mallon P, Rockstroh JK, Pozniak AL, Clotet B, Boucher CA.

J Virus Erad. 2015 Jul 1;1(3):211-20.

38.

Global Dispersal Pattern of HIV Type 1 Subtype CRF01_AE: A Genetic Trace of Human Mobility Related to Heterosexual Sexual Activities Centralized in Southeast Asia.

Angelis K, Albert J, Mamais I, Magiorkinis G, Hatzakis A, Hamouda O, Struck D, Vercauteren J, Wensing AM, Alexiev I, Åsjö B, Balotta C, Camacho RJ, Coughlan S, Griskevicius A, Grossman Z, Horban A, Kostrikis LG, Lepej S, Liitsola K, Linka M, Nielsen C, Otelea D, Paredes R, Poljak M, Puchhammer-Stöckl E, Schmit JC, Sönnerborg A, Staneková D, Stanojevic M, Boucher CA, Kaplan L, Vandamme AM, Paraskevis D.

J Infect Dis. 2015 Jun 1;211(11):1735-44. doi: 10.1093/infdis/jiu666. Epub 2014 Dec 15.

PMID:
25512631
39.

Diminished transmission of drug resistant HIV-1 variants with reduced replication capacity in a human transmission model.

Pingen M, Sarrami-Forooshani R, Wensing AM, van Ham P, Drewniak A, Boucher CA, Geijtenbeek TB, Nijhuis M.

Retrovirology. 2014 Dec 14;11:113. doi: 10.1186/s12977-014-0113-9.

40.

Increasing the use of second-line therapy is a cost-effective approach to prevent the spread of drug-resistant HIV: a mathematical modelling study.

Nichols BE, Sigaloff KC, Kityo C, Hamers RL, Baltussen R, Bertagnolio S, Jordan MR, Hallett TB, Boucher CA, de Wit TF, van de Vijver DA.

J Int AIDS Soc. 2014 Dec 5;17:19164. doi: 10.7448/IAS.17.1.19164. eCollection 2014.

41.

Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era.

Berden FA, Kievit W, Baak LC, Bakker CM, Beuers U, Boucher CA, Brouwer JT, Burger DM, van Erpecum KJ, van Hoek B, Hoepelman AI, Honkoop P, Kerbert-Dreteler MJ, de Knegt RJ, Koek GH, van Nieuwkerk CM, van Soest H, Tan AC, Vrolijk JM, Drenth JP.

Neth J Med. 2014 Oct;72(8):388-400. Review.

42.

Mutation V111I in HIV-2 reverse transcriptase increases the fitness of the nucleoside analogue-resistant K65R and Q151M viruses.

Deuzing IP, Charpentier C, Wright DW, Matheron S, Paton J, Frentz D, van de Vijver DA, Coveney PV, Descamps D; ANRS CO5 HIV-2 Cohort, Boucher CA, Beerens N.

J Virol. 2015 Jan;89(1):833-43. doi: 10.1128/JVI.02259-14. Epub 2014 Oct 29.

43.

Infection with the frequently transmitted HIV-1 M41L variant has no influence on selection of tenofovir resistance.

Pingen M, Nijhuis M, Mudrikova T, van Laarhoven A, Langebeek N, Richter C, Boucher CA, Wensing AM.

J Antimicrob Chemother. 2015 Feb;70(2):573-80. doi: 10.1093/jac/dku377. Epub 2014 Sep 26.

PMID:
25261422
44.

Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe.

Frentz D, Van de Vijver DA, Abecasis AB, Albert J, Hamouda O, Jørgensen LB, Kücherer C, Struck D, Schmit JC, Vercauteren J, Åsjö B, Balotta C, Beshkov D, Camacho RJ, Clotet B, Coughlan S, Griskevicius A, Grossman Z, Horban A, Kolupajeva T, Korn K, Kostrikis LG, Liitsola K, Linka M, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnerborg A, Stanekova D, Stanojevic M, Van Wijngaerden E, Wensing AM, Boucher CA; SPREAD Programme.

BMC Infect Dis. 2014 Jul 21;14:407. doi: 10.1186/1471-2334-14-407.

45.

Cost-effectiveness of PrEP in HIV/AIDS control in Zambia: a stochastic league approach.

Nichols BE, Baltussen R, van Dijk JH, Thuma PE, Nouwen JL, Boucher CA, van de Vijver DA.

J Acquir Immune Defic Syndr. 2014 Jun 1;66(2):221-8. doi: 10.1097/QAI.0000000000000145.

PMID:
24694930
46.

Hepatitis B virus prevalence, risk factors and genotype distribution in HIV infected patients from West Java, Indonesia.

Fibriani A, Wisaksana R, Alisjahbana B, Indrati A, Schutten M, van Crevel R, van der Ven A, Boucher CA.

J Clin Virol. 2014 Apr;59(4):235-41. doi: 10.1016/j.jcv.2014.01.012. Epub 2014 Jan 26.

PMID:
24529845
47.

Leflunomide as part of the treatment for multidrug-resistant cytomegalovirus disease after lung transplantation: case report and review of the literature.

Verkaik NJ, Hoek RA, van Bergeijk H, van Hal PT, Schipper ME, Pas SD, Beersma MF, Boucher CA, Jedema I, Falkenburg F, Hoogsteden HC, van den Blink B, Murk JL.

Transpl Infect Dis. 2013 Dec;15(6):E243-9. doi: 10.1111/tid.12156. Epub 2013 Oct 23. Review.

PMID:
24298985
48.

A polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activity.

Wright DW, Deuzing IP, Flandre P, van den Eede P, Govaert M, Setiawan L, Coveney PV, Marcelin AG, Calvez V, Boucher CA, Beerens N.

PLoS One. 2013 Oct 2;8(10):e74078. doi: 10.1371/journal.pone.0074078. eCollection 2013.

49.

Treatment of hepatitis C monoinfection in adults--Dutch national guidelines.

Lamers MH, Broekman MM, Boucher CA, Brouwer JT, Burger DM, van Hoek B, Hoepelman AI, de Knegt RJ, Reesink HW, Drenth JP; Netherlands Association of Hepato-gastroenterologists; Netherlands Association of Internal Medicine; Dutch Association for the Study of Liver Disease.

Neth J Med. 2013 Sep;71(7):377-85.

50.

Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models.

van de Vijver DA, Nichols BE, Abbas UL, Boucher CA, Cambiano V, Eaton JW, Glaubius R, Lythgoe K, Mellors J, Phillips A, Sigaloff KC, Hallett TB.

AIDS. 2013 Nov 28;27(18):2943-51. doi: 10.1097/01.aids.0000433237.63560.20.

PMID:
23939237

Supplemental Content

Loading ...
Support Center